CN116891533A - 补体抑制杂合蛋白 - Google Patents

补体抑制杂合蛋白 Download PDF

Info

Publication number
CN116891533A
CN116891533A CN202310376695.2A CN202310376695A CN116891533A CN 116891533 A CN116891533 A CN 116891533A CN 202310376695 A CN202310376695 A CN 202310376695A CN 116891533 A CN116891533 A CN 116891533A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
protein
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310376695.2A
Other languages
English (en)
Chinese (zh)
Inventor
马海立
刘恒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianchen Biomedical Suzhou Co ltd
Original Assignee
Tianchen Biomedical Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianchen Biomedical Suzhou Co ltd filed Critical Tianchen Biomedical Suzhou Co ltd
Publication of CN116891533A publication Critical patent/CN116891533A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202310376695.2A 2022-04-11 2023-04-10 补体抑制杂合蛋白 Pending CN116891533A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022103748112 2022-04-11
CN202210374811 2022-04-11

Publications (1)

Publication Number Publication Date
CN116891533A true CN116891533A (zh) 2023-10-17

Family

ID=88312629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310376695.2A Pending CN116891533A (zh) 2022-04-11 2023-04-10 补体抑制杂合蛋白

Country Status (6)

Country Link
US (1) US20250257106A1 (enExample)
EP (1) EP4509521A4 (enExample)
JP (1) JP2025512062A (enExample)
KR (1) KR20250004744A (enExample)
CN (1) CN116891533A (enExample)
WO (1) WO2023197930A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4715959A1 (en) 2024-02-29 2026-03-25 LG Energy Solution, Ltd. Method for regenerating cathode active material and regenerated cathode active material manufactured therefrom

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3066699A (en) * 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
US9540626B2 (en) * 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201706808D0 (en) * 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
EP3958901A4 (en) * 2019-04-24 2023-07-19 The Trustees of the University of Pennsylvania BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白

Also Published As

Publication number Publication date
EP4509521A4 (en) 2026-04-15
EP4509521A1 (en) 2025-02-19
JP2025512062A (ja) 2025-04-16
US20250257106A1 (en) 2025-08-14
WO2023197930A9 (zh) 2024-01-11
KR20250004744A (ko) 2025-01-08
WO2023197930A1 (zh) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7275095B2 (ja) 補体関連障害を処置するための組成物、方法およびキット
JP7505980B2 (ja) Ｃ３ｂ結合ポリペプチド
CN116891533A (zh) 补体抑制杂合蛋白
BR112013028271B1 (pt) Polipeptideo, acido nucleico, vetor viral, preparação farmaceutica, bem como uso dos mesmos no tratamento de doenqa mediada por complemento
KR20180091097A (ko) 보체 활성화를 억제하기 위한 폴리펩티드
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
JP2018522547A (ja) Ｉｌ−３７バリアント
CN106164090B (zh) TRAIL穿膜肽样突变体MuR6、制备方法及应用
CA2438334C (en) Ocular tear growth factor-like protein
JPH09501822A (ja) 精製哺乳動物ｆｌｔ３リガンド並びにそのアゴニストおよびアンタゴニスト
AU2024250682B2 (en) Aav variants for treatment of complement disorders
WO2016138618A1 (zh) TRAIL穿膜肽样突变体MuR5、制备方法及应用
EP2162463B1 (en) Vegf-d mutants and their use
EP4714979A1 (en) Biased complement inhibitory hybrid protein
CN118955727A (zh) 偏向性补体抑制杂合蛋白
JP2005506967A (ja) 高分子質量レクチンの生産
WO2021219807A1 (en) Pd-l1 variants with improved affinity towards pd-1
CN116507632A (zh) 用于抑制fgf23活性的组合物和方法
CN115073607A (zh) Tnfr2与baff受体的融合蛋白
RU2790661C2 (ru) Варианты trem2, устойчивые к действию шеддазы
WO2022011081A1 (en) Cell lines that produce human retinoschisin proteins and uses thereof
CN121517527A (zh) 工程化补体因子h相关蛋白及其应用
CN115379834A (zh) 用于nmnat1相关视网膜变性的基因疗法
CA3246911A1 (en) Thrombopoietin Receptor Fragments and Their Uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: 201203 Shanghai Pudong New Area Bi Bo Road No. 518 Room 304

Applicant after: Tianchen Biopharma (Suzhou) Co., Ltd.

Address before: 201203 Shanghai Pudong New Area Bi Bo Road No. 518 Room 304

Applicant before: Tianchen biomedical (Suzhou) Co.,Ltd.

Country or region before: China

CB02 Change of applicant information